155 related articles for article (PubMed ID: 30050595)
41. Primary central nervous system lymphoma.
Stern JI; Raizer JJ
Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S63-70. PubMed ID: 16274272
[TBL] [Abstract][Full Text] [Related]
42. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.
Grimm SA; McCannel CA; Omuro AM; Ferreri AJ; Blay JY; Neuwelt EA; Siegal T; Batchelor T; Jahnke K; Shenkier TN; Hall AJ; Graus F; Herrlinger U; Schiff D; Raizer J; Rubenstein J; Laperriere N; Thiel E; Doolittle N; Iwamoto FM; Abrey LE
Neurology; 2008 Oct; 71(17):1355-60. PubMed ID: 18936428
[TBL] [Abstract][Full Text] [Related]
43. Clinical Characteristics, Surgical Outcomes, and Prognostic Factors of Intracranial Primary Central Nervous System Lymphoma.
Ouyang T; Wang L; Zhang N; Zhang Z; Xiong Y; Li M; Hong T
World Neurosurg; 2020 Jul; 139():e508-e516. PubMed ID: 32311566
[TBL] [Abstract][Full Text] [Related]
44. Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013).
Fuentes-Raspall R; Solans M; Auñon-Sanz C; Saez M; Marcos-Gragera R
Clin Transl Oncol; 2018 Dec; 20(12):1628-1630. PubMed ID: 29796994
[No Abstract] [Full Text] [Related]
45. Central nervous system lymphoma: patterns of incidence in Indian population and effect of steroids on stereotactic biopsy yield.
Manoj N; Arivazhagan A; Mahadevan A; Bhat DI; Arvinda HR; Devi BI; Sampath S; Chandramouli BA
Neurol India; 2014; 62(1):19-25. PubMed ID: 24608449
[TBL] [Abstract][Full Text] [Related]
46. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013.
Eloranta S; Brånvall E; Celsing F; Papworth K; Ljungqvist M; Enblad G; Ekström-Smedby K
Eur J Haematol; 2018 Jan; 100(1):61-68. PubMed ID: 28983970
[TBL] [Abstract][Full Text] [Related]
47. Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study.
Lemma SA; Pasanen AK; Haapasaari KM; Sippola A; Sormunen R; Soini Y; Jantunen E; Koivunen P; Salokorpi N; Bloigu R; Turpeenniemi-Hujanen T; Kuittinen O
Eur J Haematol; 2016 May; 96(5):492-501. PubMed ID: 26153511
[TBL] [Abstract][Full Text] [Related]
48. Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors.
Downs BM; Ding W; Cope LM; Umbricht CB; Li W; He H; Ke X; Holdhoff M; Bettegowda C; Tao W; Sukumar S
Clin Epigenetics; 2021 May; 13(1):104. PubMed ID: 33952317
[TBL] [Abstract][Full Text] [Related]
49. Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis.
Panageas KS; Elkin EB; DeAngelis LM; Ben-Porat L; Abrey LE
Cancer; 2005 Dec; 104(11):2466-72. PubMed ID: 16240449
[TBL] [Abstract][Full Text] [Related]
50. Management and outcome of primary CNS lymphoma in the modern era: An LOC network study.
Houillier C; Soussain C; Ghesquières H; Soubeyran P; Chinot O; Taillandier L; Lamy T; Choquet S; Ahle G; Damaj G; Agapé P; Moluçon-Chabrot C; Amiel A; Delwail V; Fabbro M; Jardin F; Chauchet A; Moles-Moreau MP; Morschhauser F; Casasnovas O; Gressin R; Fornecker LM; Abraham J; Marolleau JP; Tempescul A; Campello C; Colin P; Tamburini J; Laribi K; Serrier C; Haioun C; Chebrek S; Schmitt A; Blonski M; Houot R; Boyle E; Bay JO; Oberic L; Tabouret E; Waultier A; Martin-Duverneuil N; Touitou V; Cassoux N; Kas A; Mokhtari K; Charlotte F; Alentorn A; Feuvret L; Le Garff-Tavernier M; Costopoulos M; Mathon B; Peyre M; Delgadillo D; Douzane H; Genet D; Aidaoui B; Hoang-Xuan K; Gyan E
Neurology; 2020 Mar; 94(10):e1027-e1039. PubMed ID: 31907289
[TBL] [Abstract][Full Text] [Related]
51. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma.
Kaulen LD; Galluzzo D; Hui P; Barbiero F; Karschnia P; Huttner A; Fulbright R; Baehring JM
J Neurooncol; 2019 Aug; 144(1):107-115. PubMed ID: 31190317
[TBL] [Abstract][Full Text] [Related]
52. BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.
Makino K; Nakamura H; Shinojima N; Kuroda JI; Yano S; Mikami Y; Mukasa A
J Neurooncol; 2018 Oct; 140(1):115-121. PubMed ID: 29968039
[TBL] [Abstract][Full Text] [Related]
53. Primary central nervous system lymphoma in Japan 1995-1999: changes from the preceding 10 years.
Shibamoto Y; Tsuchida E; Seki K; Oya N; Hasegawa M; Toda Y; Takemoto M; Sumi M; Hiratsuka J; Oguchi M; Hosono M; Yasuda S; Sougawa M; Kakutoh Y; Hayabuchi N
J Cancer Res Clin Oncol; 2004 Jun; 130(6):351-6. PubMed ID: 15034788
[TBL] [Abstract][Full Text] [Related]
54. Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.
Sun X; Wang C; Chen C; Huang J; Wu X; Wang Y; He X; Cao J; Jiang W; Sun P; Li Z
Hematol Oncol; 2021 Dec; 39(5):625-638. PubMed ID: 34543472
[TBL] [Abstract][Full Text] [Related]
55. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
[No Abstract] [Full Text] [Related]
56. [Clinical features and treatment outcomes in primary central nervous system lymphoma: a descriptive analysis of 62 patients].
Ge Y; Lin XT; Luo DL; Zhang F; Xu J; Li Z; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2019 Nov; 48(11):861-866. PubMed ID: 31775435
[No Abstract] [Full Text] [Related]
57. Second malignancies in patients with primary central nervous system lymphoma.
Wang J; Pulido JS; O'Neill BP; Johnston PB
Neuro Oncol; 2015 Jan; 17(1):129-35. PubMed ID: 24948826
[TBL] [Abstract][Full Text] [Related]
58. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
[TBL] [Abstract][Full Text] [Related]
59. A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival.
Kinch A; Baecklund E; Backlin C; Ekman T; Molin D; Tufveson G; Fernberg P; Sundström C; Pauksens K; Enblad G
Acta Oncol; 2014 May; 53(5):669-79. PubMed ID: 24164103
[TBL] [Abstract][Full Text] [Related]
60. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
